LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 83

Search options

  1. Article ; Online: In reply to the Letter to Editor regarding 'Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study'.

    Zhang, Yanfang / Ye, Ziqi / Jiang, Saiping

    International journal of antimicrobial agents

    2024  , Page(s) 107178

    Language English
    Publishing date 2024-04-25
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2024.107178
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.

    Dong, Rong / Huang, Yizhen / Ling, Xiao / Li, Lu / Yu, Wenqiao / Jiang, Saiping

    International journal of antimicrobial agents

    2023  Volume 63, Issue 1, Page(s) 106997

    Abstract: Objectives: Nirmatrelvir/ritonavir is a highly efficacious agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although dose adjustment is recommended in patients with renal impairment according to the package insert ... ...

    Abstract Objectives: Nirmatrelvir/ritonavir is a highly efficacious agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although dose adjustment is recommended in patients with renal impairment according to the package insert for Paxlovid (Pfizer), there is no dose recommendation for patients with severe renal impairment who require continuous renal replacement therapy (CRRT).
    Methods: To characterise the features of nirmatrelvir/ritonavir in critically ill Chinese patients undergoing CRRT, therapeutic drug monitoring of nirmatrelvir/ritonavir was performed by high-performance liquid chromatography tandem mass spectrometry assay in eight patients.
    Results: Nirmatrelvir trough concentrations ranged from 3325.34 ng/mL to 15 625.46 ng/mL. Concentrations were up to 7-fold higher compared with patients with normal renal function and 2-fold higher compared with patients with end-stage renal disease undergoing haemodialysis.
    Conclusions: These results suggest that a dose reduction should be implemented in the treatment of patients with CRRT.
    MeSH term(s) Humans ; Continuous Renal Replacement Therapy ; Ritonavir/therapeutic use ; Critical Illness ; SARS-CoV-2 ; Antiviral Agents/therapeutic use ; Nitriles ; Drug Combinations ; Leucine ; Proline ; Lactams
    Chemical Substances nirmatrelvir and ritonavir drug combination ; Ritonavir (O3J8G9O825) ; Antiviral Agents ; Nitriles ; Drug Combinations ; Leucine (GMW67QNF9C) ; Proline (9DLQ4CIU6V) ; Lactams
    Language English
    Publishing date 2023-10-15
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2023.106997
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study.

    Zhang, Yanfang / Dong, Rong / Huang, Yizhen / Ling, Xiao / Ye, Ziqi / Jiang, Saiping

    International journal of antimicrobial agents

    2023  Volume 63, Issue 1, Page(s) 107031

    Abstract: Objective: To compare the incidence of acute kidney injury (AKI) in patients treated with colistin sulfate (CS) and polymyxin B sulfate (PMB).: Methods: Sociodemographic and laboratory measures of adult patients who received intravenous CS or PMB for ...

    Abstract Objective: To compare the incidence of acute kidney injury (AKI) in patients treated with colistin sulfate (CS) and polymyxin B sulfate (PMB).
    Methods: Sociodemographic and laboratory measures of adult patients who received intravenous CS or PMB for at least 72 h for the first time at the study hospital from October 2021 to November 2022 were collected retrospectively. The primary outcome was the incidence of AKI, defined by the Kidney Diseases Improving Global Outcomes criteria. The secondary outcome was 30-day mortality.
    Results: In total, 109 patients were included in the CS cohort and 176 patients were included in the PMB cohort. The incidence of AKI was significantly higher in the PMB cohort compared with the CS cohort (50.6% vs. 18.3%; P<0.001). On multi-variate analysis, CS therapy [hazard ratio (HR) 0.275; P<0.001] was an independent protective factor for AKI, along with higher estimated glomerular filtration rate. Nevertheless, 30-day mortality was similar in the PMB and CS cohorts (21.6% vs. 13.8%; P=0.099). Multi-variate analyses revealed that CS therapy was not associated with 30-day mortality (HR 0.968; P=0.926), while intensive care unit admission, combination with meropenem, Charlson score and stage 3 AKI were independent risk factors for 30-day mortality. After balancing the baseline characteristics of patients using propensity score matching, the main results were unchanged.
    Conclusion: The incidence of AKI was significantly lower in the CS cohort compared with the PMB cohort. However, 30-day mortality was similar in the two cohorts.
    MeSH term(s) Adult ; Humans ; Polymyxin B/adverse effects ; Colistin/adverse effects ; Anti-Bacterial Agents/adverse effects ; Retrospective Studies ; Acute Kidney Injury/chemically induced ; Acute Kidney Injury/epidemiology ; Risk Factors
    Chemical Substances Polymyxin B (J2VZ07J96K) ; Colistin (Z67X93HJG1) ; Anti-Bacterial Agents
    Language English
    Publishing date 2023-11-10
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2023.107031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Anti-VEGFR2 F(ab')

    Liu, Di / Song, Yanling / Chen, Hui / You, Yuchan / Zhu, Luwen / Zhang, Jucong / Xu, Xinyi / Hu, Jiahao / Huang, Xiajie / Wu, Xiaochuan / Xu, Xiaoling / Jiang, Saiping / Du, Yongzhong

    Nature communications

    2023  Volume 14, Issue 1, Page(s) 8268

    Abstract: Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab') ...

    Abstract Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab')
    MeSH term(s) Animals ; Mice ; Male ; Diabetic Nephropathies/drug therapy ; Diabetic Nephropathies/metabolism ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor Receptor-2/metabolism ; Antibodies, Monoclonal/pharmacology ; Immunoglobulin Fab Fragments ; Kidney/metabolism ; Immunoconjugates/pharmacology ; Diabetes Mellitus/metabolism
    Chemical Substances Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factor Receptor-2 (EC 2.7.10.1) ; Antibodies, Monoclonal ; Immunoglobulin Fab Fragments ; Immunoconjugates
    Language English
    Publishing date 2023-12-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-43847-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: The temperature increase in Greenland has accelerated in the past five years

    Jiang, Saiping / Ye, Aizhong / Xiao, Cunde

    Global and planetary change. 2020 Nov., v. 194

    2020  

    Abstract: Understanding the changes in Greenland's temperature is important for assessing and predicting the mass of the Greenland ice sheet, which plays an important role in sea level rise. In this study, we analyzed the annual and seasonal coastal Greenland's ... ...

    Abstract Understanding the changes in Greenland's temperature is important for assessing and predicting the mass of the Greenland ice sheet, which plays an important role in sea level rise. In this study, we analyzed the annual and seasonal coastal Greenland's temperatures during the period 1952–2017 (focusing on the period 2013–2017) based on a dataset obtained from the Danish Meteorological Institute (DMI). Overall, the annual coastal Greenland's temperature increased during 1952–2017 at a rate of 0.23 °C decade⁻¹, especially in the southeastern (0.70 °C decade⁻¹) and northern (0.42 °C decade⁻¹) regions of the island. From the changes in the seasonal coastal Greenland's composite temperature (CT), winter exhibited the largest change rate (0.28 °C decade⁻¹), and the summer CT increased by 0.25 °C decade⁻¹, while the spring CT increased by 0.17 °C decade⁻¹ with less variation. The temperature increase accelerated during 2013–2017 according to Mann-Kendall (M-K) tests, especially in the northeastern and northern regions of the island. The seasonal temperature change of the whole island decreased in the following order: annual > autumn > summer > winter > spring. We also analyzed the annual inland temperature change during the period 1997–2017 based on a dataset obtained from the Greenland Climate Network; the results indicated that the inland temperature increased by 0.13 °C decade⁻¹. Pearson correlation analysis was used to determine the teleconnection relationship between the coastal temperatures and large-scale atmosphere-ocean climate indexes, and we found that the Greenland Blocking Index (GBI), Atlantic Multidecadal Oscillation (AMO), Tropical Northern Atlantic Index (TNA), North Tropical Atlantic Index (NTA), Caribbean Index (CAR), Atlantic Meridional Mode (AMM), East Atlantic (EA) and Western Hemisphere warm pool (WHWP) have significant positive correlations with the coastal temperature in most months, except in February and May. However, the North Atlantic Oscillation (NAO), Arctic Oscillation (AO) and Eastern Asia/Western Russia (EAWR) show significant negative correlations with temperature. Overall, there exists a time lag effect between the climate indexes (except for the GBI, AO and NAO) and temperature. From the application of the random forest model, we found that the GBI, NAO, CO₂, AMO, N₂O, SF₆, CH₄, and Northern Oscillation Index (NOI) are the most important variables that influenced the CT changes during 1979–2017. Finally, we calculated the contribution rates of the most important variables to temperature change during the period 1979–2017 and showed that the contribution rates of the GBI, CO₂ and NOI to temperature change were 47.30%, 35.68%, and 17.02%, respectively.
    Keywords North Atlantic Oscillation ; algorithms ; autumn ; carbon dioxide ; climate ; data collection ; ice ; methane ; nitrous oxide ; prediction ; sea level ; spring ; sulfur hexafluoride ; summer ; temperature ; winter ; Arctic region ; Caribbean ; East Asia ; Greenland ; Russia
    Language English
    Dates of publication 2020-11
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 2016967-X
    ISSN 0921-8181
    ISSN 0921-8181
    DOI 10.1016/j.gloplacha.2020.103297
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article ; Online: Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.

    Hu, Yunzhen / Zuo, Minjuan / Wang, Xiaojuan / Wang, Rongrong / Li, Lu / Lu, Xiaoyang / Jiang, Saiping

    Journal of Zhejiang University. Science. B

    2021  Volume 22, Issue 7, Page(s) 599–602

    Abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing (January ...

    Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing (January 2, 2021). Since there are no targeted therapies for COVID-19, the current focus is the repurposing of drugs approved for other uses. In some clinical trials, antiviral drugs such as remdesivir (Grein et al., 2020), lopinavir/ritonavir (LPV/r) (Cao et al., 2020), chloroquine (Gao et al., 2020), hydroxychloroquine (Gautret et al., 2020), arbidol (Wang et al., 2020), and favipiravir (Cai et al., 2020b) have shown efficacy in COVID-19 patients. LPV/r combined with arbidol, which is the basic regimen in some regional hospitals in China including Zhejiiang Province, has shown antiviral effects in COVID-19 patients (Guo et al., 2020; Xu et al., 2020). A retrospective cohort study also reported that this combination therapy showed better efficacy than LPV/r alone for the treatment of COVID-19 patients (Deng et al., 2020).
    MeSH term(s) Animals ; Drug Interactions ; Drug Therapy, Combination ; Female ; Indoles/administration & dosage ; Indoles/pharmacokinetics ; Lopinavir/administration & dosage ; Lopinavir/pharmacokinetics ; Male ; Rats ; Retrospective Studies ; Ritonavir/administration & dosage ; Ritonavir/pharmacokinetics ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Indoles ; Lopinavir (2494G1JF75) ; umifenovir (93M09WW4RU) ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2021-07-16
    Publishing country China
    Document type Journal Article
    ZDB-ID 2247290-3
    ISSN 1862-1783 ; 1673-1581
    ISSN (online) 1862-1783
    ISSN 1673-1581
    DOI 10.1631/jzus.B2000728
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy

    Di Liu / Yanling Song / Hui Chen / Yuchan You / Luwen Zhu / Jucong Zhang / Xinyi Xu / Jiahao Hu / Xiajie Huang / Xiaochuan Wu / Xiaoling Xu / Saiping Jiang / Yongzhong Du

    Nature Communications, Vol 14, Iss 1, Pp 1-

    2023  Volume 14

    Abstract: Abstract Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti- ... ...

    Abstract Abstract Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)2) to block VEGFR2 overactivation in diabetic nephropathy (DN). We find that the anti-VEGFR2 F(ab′)2 has a higher accumulation in DN male mice kidneys than the intact VEGFR2 antibody, and simultaneously preserves the binding ability to VEGFR2. Furthermore, we develop an antibody fragment drug conjugate, anti-VEGFR2 F(ab′)2-SS31, comprising the anti-VEGFR2 F(ab′)2 fragment linked to the mitochondria-targeted antioxidant peptide SS31. We find that introduction of SS31 potentiates the efficacy of anti-VEGFR2 F(ab′)2. These findings provide proof of concept for the premise that antibody fragment drug conjugate improves renal distribution and merits drug validation in renal disease therapy.
    Keywords Science ; Q
    Subject code 616
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Book ; Online: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

    Li, Lu / Wang, Xiaojuan / Wang, Rongrong / Hu, Yunzhen / Jiang, Saiping / Lu, Xiaoyang

    2020  

    Abstract: Lu Li, Xiaojuan Wang, Rongrong Wang, Yunzhen Hu, Saiping Jiang, Xiaoyang Lu Department of Pharmacy ... of ChinaCorrespondence: Xiaoyang Lu; Saiping Jiang Email luxiaoyang@zju.edu.cn; j5145@zju.edu.cnAbstract: Coronavirus ...

    Abstract Lu Li, Xiaojuan Wang, Rongrong Wang, Yunzhen Hu, Saiping Jiang, Xiaoyang Lu Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of ChinaCorrespondence: Xiaoyang Lu; Saiping Jiang Email luxiaoyang@zju.edu.cn; j5145@zju.edu.cnAbstract: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.Keywords: coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, antiviral therapy, special population
    Keywords Drug Design ; Development and Therapy ; covid19
    Subject code 610
    Language English
    Publishing date 2020-07-28
    Publisher Dove Press
    Publishing country us
    Document type Article ; Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

    Li, Lu / Wang, Xiaojuan / Wang, Rongrong / Hu, Yunzhen / Jiang, Saiping / Lu, Xiaoyang

    Drug Design, Development and Therapy

    2020  Volume Volume 14, Page(s) 3001–3013

    Keywords Pharmacology ; Drug Discovery ; Pharmaceutical Science ; covid19
    Language English
    Publisher Informa UK Limited
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 2451346-5
    ISSN 1177-8881
    ISSN 1177-8881
    DOI 10.2147/dddt.s259058
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.

    Li, Lu / Wang, Xiaojuan / Wang, Rongrong / Hu, Yunzhen / Jiang, Saiping / Lu, Xiaoyang

    Drug design, development and therapy

    2020  Volume 14, Page(s) 3001–3013

    Abstract: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of ... ...

    Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.
    MeSH term(s) Aged ; Antiviral Agents/adverse effects ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Critical Illness ; Female ; Humans ; Kidney Diseases/complications ; Liver Diseases/complications ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; Pregnancy ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents
    Keywords covid19
    Language English
    Publishing date 2020-07-28
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S259058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top